Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

6 May 2020

Abstract excerpt

PURPOSE: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; "tavo") electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cutaneous Melanoma Detection and Management
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32376655
DOI: 10.1158/1078-0432.ccr-19-2217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent MelanomaPMID 32376655Read ↗

Intratumoral expression of IL-12 and CD40 ligand (CD154) from plasmids generates antitumor responses that eliminate tumoral T regsSemantic proximity Read ↗

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialSemantic proximity Read ↗

The effectiveness of calcium electroporation combined with gene electrotransfer of a plasmid encoding IL-12 is tumor type-dependentSemantic proximity Read ↗

Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumorsSemantic proximity Read ↗

Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck regionSemantic proximity Read ↗

IFN-α and 5-Aza-2’-deoxycytidine enhance the anti-tumor efficacy of a dendritic- cell targeting MIP3a-Gp100-Trp2 DNA vaccine by affecting T-cell recruitment and tumor microenvironment gene expressionSemantic proximity Read ↗

Mutational burden, MHC-I expression and immune infiltration as limiting factors for in situ vaccination by TNFα and IL-12 gene electrotransfer.Semantic proximity Read ↗

Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy.Semantic proximity Read ↗

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.Semantic proximity Read ↗

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trialSemantic proximity Read ↗

Non-clinical evaluation of pmIL12 gene therapy for approval of the phase I clinical studySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.